The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
 
Thomas Lillie
Employment - Grey Wolf Therapeutics Ltd; PsiOxus Therapeutics
Leadership - Grey Wolf Therapeutics Ltd; PsiOxus Therapeutics
Stock and Other Ownership Interests - Grey Wolf Therapeutics; PsiOxus Therapeutics
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Jia (Jenny) Liu
Honoraria - MSD; Specialised Therapeutics
Consulting or Advisory Role - Greywolf Therapeutics (Inst); Starpharma (Inst)
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - ImmVirX; MSD; Starpharma
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Haakan Jakobsson
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Hui Kong Gan
Consulting or Advisory Role - Bristol-Myers Squibb; Curis; Grey Wolf Therapeutics; Merck Serono; SERVIER; Telix Pharmaceuticals
 
Peter Joyce
Employment - Grey Wolf Therapeutics
Leadership - Grey Wolf Therapeutics
Stock and Other Ownership Interests - Grey Wolf Therapeutics
Research Funding - Grey Wolf Therapeutics
 
Natalie Hyland
Employment - Adaptimmune; Grey Wolf Therapeutics
Stock and Other Ownership Interests - Adaptimmune; Grey Wolf Therapeutics
Research Funding - Adaptimmune; Grey Wolf Therapeutics
 
Mara Giovannetti
Employment - BeiGene; Grey Wolf Therapeutics
Stock and Other Ownership Interests - BeiGene; Grey Wolf Therapeutics
Research Funding - Adaptimmune; BeiGene
 
Tanya Palmer
Stock and Other Ownership Interests - Grey Wolf Therapeutics
Consulting or Advisory Role - Adaptimmune; Enara Bio; Grey Wolf Therapeutics; QBiotics
Research Funding - Adaptimmune; Enara Bio; Grey Wolf Therapeutics; QBiotics
 
Cheryl McAlpine
Employment - Adaptimmune; Grey Wolf Therapeutics
Stock and Other Ownership Interests - Adaptimmune; Grey Wolf Therapeutics
Research Funding - Adaptimmune; Grey Wolf Therapeutics
 
Daniel Green
Employment - M:M Bio Limited
Stock and Other Ownership Interests - Grey Wolf Therapeutics
Consulting or Advisory Role - Myricx Pharma
 
Stefan N. Symeonides
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); Eugit Therapeutics (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Eisai (Inst); EUSA Pharma (Inst); Ipsen (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Medannex (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Scancell (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD